infliximabe no tratamento da psoríase grave

INFLIXIMABE NO TRATAMENTO DA PSORÍASE GRAVE
(Psoriasis) OR (Psoriases) OR (Pustulosis of Palms and Soles) OR (Palmoplantaris
Pustulosis) OR (Pustulosis Palmaris et Plantaris) OR (Pustular Psoriasis of Palms and
Soles)
(infliximab) OR (MAb cA2 ) OR (monoclonal antibody cA2 ) OR (Remicade) OR
(Centocor brand of infliximab) OR (Essex brand of infliximab) OR (Schering brand of
infliximab) OR (Schering-Plough brand of infliximab)
BIREME/PAHO/WHO - Virtual Health Library
Database :
Search on :
Total of references :
LILACS
(Psoriasis) OR (Psoriases) OR (Pustulosis of Palms and Soles)
OR (Palmoplantaris Pustulosis) OR (Pustulosis Palmaris et
Plantaris) OR (Pustular Psoriasis of Palms and Soles)
[Words] and (infliximab) OR (MAb cA2 ) OR (monoclonal
antibody cA2 ) OR (Remicade) OR (Centocor brand of
infliximab) OR (Essex brand of infliximab) OR (Schering brand
of infliximab) OR (Schering-Plough brand of infliximab)
[Words]
3
1/3
Id: 418796
Author: Loyola, Adriano Jaime Consorte; Castro, Lia Cândida Miranda de; Chaibub,
Sulamita Costa Wirth; Ximenes, Antônio Carlos.
Title: Infliximab no tratamento da artrite psoriásica grave / Infliximab in treatment of
severe psoriatic arthritis
Source: An. bras. dermatol;80(5):535-537, set.-out. 2005. ilus.
Language: Pt.
Abstract: A artrite psoriásica tem sido reconhecida como doenca imunomediada, em
que há participacäo de células T produtoras de citocinas (fator de necrose
tumoral-alfa). O infliximab é anticorpo monoclonal que se liga e inativa o fator
de necrose tumoral-alfa. Relata-se um caso de artrite psoriásica grave,
refratária a várias terapêuticas sistêmicas, tratado com infliximab 5mg/kg, em
infusäo venosa de três horas, nas semanas 0, 2, 6 e 14, associado com baixa
dose de metotrexato, que apresentou excelente resposta terapêutica. (AU).
Descriptors: Arthritis, Psoriatic
Tumor Necrosis Factor
Psoriasis
Tipo de Publicação: Comparative Study
Responsable: BR461.1 - SOC.BRAS.DERMATOLOGIA/Bteca
2/3
Id: 396086
Author: Tejos Avello, Loreto; Díaz, Yolimar; Páez, Erika.
Title: Eritrodermia psoriática: respuesta al tratamiento con infliximab / Psoriatic
erythroderma: answer to the treatment with infliximab
Source: Dermatol. venez;41(1):24-27, 2003. ilus, graf.
Language: Es.
Abstract: La psoriasis es una enfermedad autoinmune, crónica; que hoy se reconoce
que está mediada por los linfocitos T, asociada a señales co-estimulatorias
cuya función principal es la secreción de citoquinas. En la actualidad existen
nuevos productos biológicos capaces de inhibir algunas citoquinas, como el
factor de necrosis tumoral alfa (FNT) la cual intervienen en este intrincado
proceso. Presentamos una paciente de 35 años con diagnóstico de psoriasis
en placa desde 1989, que recibió múltiples tratamientos (corticosteroides
tópicos, derivados de la vitamina D, UVB, PUVA, metrotrexano, acitretino,
ciclosporina, colchicina). Desde el año 2001 presenta eritrodermia psoriática a
tratamiento, por lo que se decide el uso de infliximab (anticuerpo monoclonal
contra el factor de necrosis tumoral alfa) a una dosis de 3 mg/kg peso.
Después de la segunda semana de haber recibido el tratamiento, experimentó
una mejoría notable de la psoriasis, con una reducción de un 81 por ciento de
PAST con respecto al ingreso la cual ha persistido después de 5 dosis(AU).
Descriptors: Psoriasis/therapy
Dermatitis, Exfoliative/therapy
Antibodies, Monoclonal/therapeutic use
Tumor Necrosis Factor/therapeutic use
-Venezuela
Dermatology
Limits: Human
Adult
Female
Tipo de Publicação: Case Reports [Publication Type]
Responsable: VE1.1 - Un.Centr.Venez/SINADIB
3/3
Id: 355980
Author: Labarca, C; Massardo, L; García, P. I; Jacobelli, S.
Title: Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria
refractaria a drogas habituales / Effectiveness of infliximab in patients with
inflammatory arthritis refractory to conventional treatment
Source: Rev. méd. Chile;131(10):1157-1164, oct. 2003.
Language: Es.
Abstract: BACKGROUND: Tumor necrosis factor antagonists are useful in the treatment of
several chronic inflammatory immune mediated diseases. AIM: To assess the
effects of infliximab in 21 patients with inflammatory arthropaties, refractary to
conventional treatment. PATIENTS AND METHODS: Eleven patients with
rheumatoid arthritis, seven with psoriatic arthritis and three with spondyloarthritis
were treated. The mean duration of the diseases was 10 years. Infliximab was
administered intravenously in a dose of 3 mg/kg body weight. A median of 6 doses
in 8 months was administered. Effectiveness was assessed in 19 patients that
received three or more doses. RESULTS: Infliximab was effective in 16 patients
(10 with rheumatoid arthritis, four with psoriasis and two with spondyloarthritis) and
ineffective in three. In responsive patients, a reduction in the number of inflammed
joints and morning stiffness and an improvement in functional capacity was
observed. Fifteen of the 16 patients perceived an improvement in their health
status. This answer was concordant with concomitant medical evaluation in 15.
Patients that maintained the treatment felt very well, well or regular, whereas five of
six patients that discontinued the treatment felt ill. Thirteen patients had adverse
effects. Treatment was discontinued in two patients due to drug induced lupus,
allergy in 2, hypertension in one, high costs in three and lack of response in three.
CONCLUSIONS: Infliximab reduced arthritic activity in 16 of 19 patients with
severe treatment refractary arthritis. (AU).
Descriptors: Antibodies, Monoclonal/therapeutic use
Antirheumatic Agents/therapeutic use
Arthritis/drug therapy
-Arthritis, Psoriatic/drug therapy
Arthritis, Rheumatoid/drug therapy
Drug Resistance
Spondylarthritis/drug therapy
Treatment Outcome
Tumor Necrosis Factor/antagonists & inhibitors
Limits: Human
Male
Female
Adult
Middle Aged
Responsable: CL12.1